Ivan Felipe Gutierrez-Tobar

Ivan Felipe Gutierrez-Tobar

Auto-generated profile, based on publicly available information

Ivan Felipe Gutierrez-Tobar

Clínica Infantil Santa Maria del Lago y Clinica Infantil Colsubsidio , Bogota, Distrito Capital de Bogota , Colombia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
CGCamacho-Moreno Germán
Camacho-Moreno Germán
LILuisa F. Imbachi
Luisa F. Imbachi
ALAura Lucia Leal
Aura Lucia Leal
VMVivian M. Moreno
Vivian M. Moreno
JPJaime A. Patiño
Jaime A. Patiño
AMAnita Montañez
Anita Montañez
Introduction: With the use of pneumococcal conjugate vaccines(PCV), the behavior of invasive pneumococcal disease(IPD) has changed relative to serotype distribution. The introduction of these vaccines in national immunization programs has reduced the incidence of IPD, with a marked decrease in the circulation of the serotypes included in the vaccine used in each country. However, the subsequent emergence of other serotypes not included in the vaccine, such 19A in case of PCV7 and PCV10, has been documented. Materials and methods: This was case series study (2008–2017) in pediatric patients admitted to 10 hospitals in Bogota who were diagnosed with IPD. It was conducted during the transitional period of implementing the PCV10 vaccine in Colombia in 2012. Cases of bacteremic pneumococcal pneumonia, meningitis, primary bacteremia and osteoarticular infection were included. A descriptive analysis of the demographic, clinical and laboratory variables of patients with IPD by Spn19A, its trend over time, profiles of antimicrobial susceptibility and clinical outcomes was performed. Results: There were 463 cases of IPD, 315(68%) with known serotypes. The prevalence of IPD by Spn19A was 17.7%(56 cases), tending to increase over time. During 2008–2011, the prevalence was 4.4%, and during 2014–2017, it was 32.4%, The most frequent diagnosis was pneumonia(80.4%). In nonmeningeal isolates, 39.6% were not susceptible to penicillin. An increase in the resistance was observed over time. Conclusion: Spn19A is a prevalent cause of IPD in the pediatric population of the analyzed cohort, with an increasing trend of this serotype during the surveillance period after the introduction of PCV10, being the most common serotype identified in recent years.

13 March 2023 in American Journal of Infection Control
Verified
Journal Article
Closed access
VRVictor Daniel Rosenthal
Victor Daniel Rosenthal
ZJZhilin Jin
Zhilin Jin
SVSandra Liliana Valderrama-Beltran
Sandra Liliana Valderrama-Beltran
SGSandra Milena Gualtero
Sandra Milena Gualtero
CLClaudia Yaneth Linares
Claudia Yaneth Linares
RYRuijie Yin
Ruijie Yin

18 January 2023 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
IGIvan F. Gutierrez-Tobar
Ivan F. Gutierrez-Tobar
CBClaudia Beltran-Arroyave
Claudia Beltran-Arroyave
ADAlejandro Díaz
Alejandro Díaz
JLJuan P. Londoño
Juan P. Londoño
KJKaren L. Jimenez
Karen L. Jimenez
CACarlos A. Alvarez-Moreno
Carlos A. Alvarez-Moreno

28 February 2025 in Pediatric Pulmonology
Verified
Journal Article
Closed access
CBClaudia Burgos
Claudia Burgos
LMLaura Melissa Mendez
Laura Melissa Mendez
MRMaría Margarita Rodriguez
María Margarita Rodriguez
AMArianna Martinez
Arianna Martinez
PSPaola Sanchez
Paola Sanchez
EGEpico‐Colombia And Epico‐Aep Working Groups
Epico‐Colombia And Epico‐Aep Working Groups

1 November 2022 in JCO Global Oncology
Verified
Journal Article
Open access
MCMiguela Ayala CANIZA
Miguela Ayala CANIZA
MHMaysam R. Homsi
Maysam R. Homsi
MVMilka Vázquez
Milka Vázquez
IGIvan F. Gutierrez
Ivan F. Gutierrez
IKIoannis Kopsidas
Ioannis Kopsidas
MMMonika Metzger
Monika Metzger
PURPOSE: Children with cancer are at high risk for poor outcomes, and health care providers are often unfamiliar with best practices in infection care and prevention (IC&P) in this small and fragile population. Graduates of training courses in IC&P in immunocompromised hosts identified a need for a community that would enable members to share health care experiences, provide resources for continuing medical education, and foster collaborative research and quality improvement opportunities. We developed a Latin American network, Prevencionistas e Infectólogos para Cáncer Pediátrico en América Latina, to grow and sustain the expertise of the clinical workforce in IC&P. Here, we describe the network, how we built it, and its early outcomes. METHODS: We began by codesigning the mission, vision, objectives, and values. We then established the structure for leadership and network management to provide a functional uniformity and sustainability. Virtual meetings with network members and strategic in-person gatherings optimized the use of the time and resources of the network. RESULTS: The network has seen good participation by members and candidates for membership, who have provided feedback on case-based learning. Members have attended training sessions on quality improvement, research in human subjects, and IC&P in pediatric oncology at national and regional meetings and workshops. Network members have presented their work at regional and global meetings, and publications are beginning to emerge from this community. A direct effect of the Prevencionistas e Infectólogos para Cáncer Pediátrico en América Latina network has been the creation of a similar network for the Asia Pacific region, and a third network is being planned. CONCLUSION: We have demonstrated the power of a discipline-specific network structure to facilitate sharing of evidence-based information that enhances the quality-of-care delivery in pediatric oncology.

13 February 2024 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Closed access
PDF file
IGIvan F Gutierrez-Tobar
Ivan F Gutierrez-Tobar
CBClaudia Beltran-Arroyave
Claudia Beltran-Arroyave
JRJuan P Rojas-Hernandez
Juan P Rojas-Hernandez
AAAndres F Arias-Sanchez
Andres F Arias-Sanchez
JLJuan P Londoño
Juan P Londoño
JGJulián C Galvis-Ayala
Julián C Galvis-Ayala
Ivan F Gutierrez-Tobar, MD, Claudia Beltran-Arroyave, MD, Juan P Rojas-Hernandez, Andres F Arias-Sanchez, MD, Juan P Londoño, MD, Julián C Galvis-Ayala, MD; My